ZMYND11/BS69 (E7P9O) Rabbit mAb #67713

ZMYND11, also commonly referred to as BS69, is a ubiquitous chromatin reader protein that recognizes tri-methyl histone H3 lysine 36 (H3K36me3) and acts as a transcriptional repressor. It contains several domains associated with chromatin reader proteins, including an N-terminal PHD finger, a bromodomain, a PWWP domain, and a C-terminal MYND domain (1), and it shares a similar domain organization with its homolog protein ZMYND8/RACK7 (2). ZMYND11 specifically recognizes and binds to H3K36me3 modification sites on histone variant H3.3 (but not H3.1 nor H3.2), and modulates RNA Polymerase II-mediated elongation (3). ZMYND11 colocalizes with areas of high gene expression and associates with transcription factors such as E1A, MGA, Ets-2, c-Myb, and B-Myb (4). Due to its ability to repress oncogene expression, ZMYND11 is considered to be a tumor suppressor and is found to be downregulated, mutated, translocated, and show copy number variations in many types of cancer. Low levels of ZMYND11 correlate with poor prognosis in breast cancer, whereas its overexpression suppresses cancer cell growth in vivo and tumor formation in mice (3). Translocation of ZMYND11-MBTD1 is associated with acute myeloid leukemia (AML) (5-6). Copy number variations have been associated with multiple hematological disorders, including AML, acute lymphoblastic leukemia (ALL), and multiple myeloma (MM), among others (7). Translocations and mutations of ZMYND11 have also been found to be associated with autism and other neuropsychiatric and intellectual disabilities (7).